Atlas Trials

Paratek Pharmaceuticals Inc

12 clinical trials · Sponsor

Sort:Newest firstOldest first

◉ Watch Paratek Pharmaceuticals Inc

RecordFirmDate
Study to Evaluate the PK of IV and PO Omadacycline in Children and Adolescents With Suspected or Confirmed Bacterial Infections (NCT05217537)Paratek Pharmaceuticals Inc2022-04-06
Oral Omadacycline vs. Placebo in Adults With NTM Pulmonary Disease Caused by Mycobacterium Abscessus Complex (MABc) (NCT04922554)Paratek Pharmaceuticals Inc2021-10-15
Omadacycline vs. Moxifloxacin for the Treatment of Community-Acquired Bacterial Pneumonia (NCT04779242)Paratek Pharmaceuticals Inc2021-02-25
Study to Evaluate the PK of PO Omadacycline in Adults With Community-Acquired Bacterial Pneumonia (NCT04160260)Paratek Pharmaceuticals Inc2019-11-28
IV or IV/PO Omadacycline vs. IV/PO Levofloxacin for the Treatment of Acute Pyelonephritis (NCT03757234)Paratek Pharmaceuticals Inc2018-11-19
Oral Omadacycline vs. Oral Nitrofurantoin for the Treatment of Cystitis (NCT03425396)Paratek Pharmaceuticals Inc2018-01-04
Oral Omadacycline vs. Oral Linezolid for the Treatment of ABSSSI (NCT02877927)Paratek Pharmaceuticals Inc2016-08-01
Omadacycline vs Moxifloxacin for the Treatment of CABP (EudraCT #2013-004071-13) (NCT02531438)Paratek Pharmaceuticals Inc2015-11-01
Omadacycline Versus Linezolid for the Treatment of ABSSSI (EudraCT #2013-003644-23) (NCT02378480)Paratek Pharmaceuticals Inc2015-06-01
Phase 3 Study - Safety and Efficacy of PTK 0796 in Patients With Complicated Skin and Skin Structure Infection (CSSSI) (NCT00876850)Paratek Pharmaceuticals Inc2009-07-01
Study the Safety and Efficacy of PTK 0796 in Patients With Complicated Skin and Skin Structure Infection (CSSSI) (NCT00865280)Paratek Pharmaceuticals Inc2009-04-04
Study the Efficacy and Safety of PTK 0796 in Patients With Complicated Skin and Skin Structure Infection (CSSSI) (NCT03716024)Paratek Pharmaceuticals Inc2007-07-18

Track Paratek Pharmaceuticals Inc automatically

Every clearance here is in the API, with alerts when new ones post.